Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The frequency distribution of AEs was similar in both treatment groups: for ARA 290, 54 mild, 9 moderate and 1 severe categorizations were recorded, while for placebo, 61 mild and 5 moderate were noted
Some studies suggest it may support cartilage repairan exciting possibility considering cartilages poor natural healing ability
A 2002 review in Growth Hormone and IGF Research covering over 1,000 treated patients found no evidence of increased cancer risk, glucose intolerance, or antibody-mediated resistance with long-term use
Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD)
Significant amounts of phthalates and their metabolites are found in urine, breast milk, blood serum, venous blood, and umbilical cord blood
